Company: ABBV
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001551152-25-000040
Chunk: 39

Company: AbbVie Inc.
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 1
Chunk 39
---
 3 – Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company’s management about the assumptions market participants would use in pricing the asset or liability.The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of June 30, 2025:Basis of fair value measurement(in millions)TotalQuoted prices in active markets for identical assets (Level 1)Significant other observable inputs (Level 2)Significant unobservable inputs (Level 3)AssetsCash and equivalents$6,467 $6,163 $304 $— Money market funds and time deposits10 — 10 — Debt securities33 — 33 — Equity securities101 64 37 — Interest rate swap contracts60 — 60 — Foreign currency contracts41 — 41 — Total assets$6,712 $6,227 $485 $— LiabilitiesInterest rate swap contracts$104 $— $104 $— Foreign currency contracts776 — 776 — Financing liability358 — — 358 Contingent consideration24,649 — — 24,649 Total liabilities$25,887 $— $880 $25,007 

2025 Form 10-Q | 14

The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2024:Basis of fair value measurement(in millions)TotalQuoted prices in active markets for identical assets (Level 1)Significant other observableinputs (Level 2)Significant unobservable inputs (Level 3)AssetsCash and equivalents$5,524 $5,179 $345 $— Money market funds and time deposits10 — 10 — Debt securities33 — 33 — Equity securities98 70 28 — Foreign currency contracts313 — 313 — Total assets$5,978 $5,249 $729 $— LiabilitiesInterest rate swap contracts$231 $— $231 $— Foreign currency contracts35 — 35 —